NCT01255774

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The New York Eye & Ear Infirmary · Academic / Other
• Sex: All
• Age: 51 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	ranibizumab	An open-label, study of intravitreally administered ranibizumab

Timeline

• Start date: 2007-06-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2010-12-07
• Last updated: 2011-12-05

Locations

1 site across 1 country: United States